Archer Materials (ASX:AXE) is advancing into the feasibility stage the development of the graphene field effect transistor (gFET) sensors for its Biochip, according to a Thursday filing with the Australian bourse.
The company built a dataset of the sensor's performance to advance the feasibility development of the Biochip for its application in blood potassium testing for chronic kidney disease, the filing said.
Archer Materials developed an initial electrical conditioning procedure, which sets individual gFETs to a state of high repeatability. This conditioning resulted in a tenfold improvement in voltage sweeping repeatability, directly enhancing the accuracy of potassium measurements, per the filing.
The company has also completed a round of benchmarking experiments with collaborators at RMIT University to further validate the performance entitlements of gFET sensors.
Archer Materials shares rose almost 2% in recent Friday trade.
Price (AUD): $0.31, Change: $+0.01, Percent Change: +1.64%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。